Type 2 Diabetes (T2D) Clinical Trials

Find Type 2 Diabetes (T2D) Clinical Trials Near You

Evaluation of Autologous Adipose-Derived Stromal Vascular Fraction Obtained by 1210-nm Laser Photostimulation for the Treatment of Type 2 Diabetes Mellitus

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM). Adipose tissue will be harvested using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method), followed by centrifugation without enzymatic digestion. The isolated SVF will be injected endoluminally into the duodenal submucosa during the same surgical procedure. Five adult patients with T2DM will be followed for six months to assess metabolic control, pancreatic function, and quality of life outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Both sexes

• Diagnosis of Type 2 Diabetes Mellitus for less than 10 years

• BMI ≥ 25 kg/m²

• HbA1c between 7.5% and 9.5%

• C-peptide \> 1.0 nmol/L

• Use of metformin and/or pioglitazone, with or without sulfonylurea

Locations
Other Locations
Brazil
Kaiser Clinica
RECRUITING
São Jose Do Rio Preto
Contact Information
Primary
Luiz Gustavo' Quadros, PhD
gustavo_quadros@hotmail.com
+55 17 98138-8737
Time Frame
Start Date: 2025-01-20
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 10
Treatments
Experimental: Autologous SVF Duodenal Injection
Participants with Type 2 Diabetes Mellitus will undergo abdominal adipose tissue harvesting using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method). The lipoaspirate will be processed by centrifugation without enzymatic digestion to isolate stromal vascular fraction (SVF) enriched with mesenchymal stem cells. The isolated SVF will be injected into the duodenal submucosa during the same surgical procedure. Participants will be followed for six months to assess metabolic outcomes and safety.
Related Therapeutic Areas
Sponsors
Leads: Kaiser Clinic and Hospital

This content was sourced from clinicaltrials.gov